ClearOne receives Nasdaq bid-price deficiency notice; 180-day cure period started Aug 1

CLEARONE INC

Nasdaq letter on Aug 1, 2023: CLRO common stock bid below $1.00 for 30 consecutive trading days.
Must regain compliance by Jan 29, 2024 by closing at or above $1.00 for 10 consecutive days.
If not cured, may qualify for additional 180-day period if all other listing standards are met.
Company may effect a reverse stock split to cure the deficiency; no assurance of compliance.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.